Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Oneness Biotech CoLUX:ONEA 59 PB Ratio is 6.86 as of Jul. 18, 2026, which is 117% above its 10-year median of 3.16. GuruFocus rates LUX:ONEA with a GF Score™ of 59/100 and a GF Value™ of $35.65. The stock has 4 warning signs investors should review. Among 1,227 Biotechnology companies, Oneness Biotech Co ranks better than 58.03% on this metric.
The historical rank and industry rank for Oneness Biotech Co's PB Ratio or its related term are showing as below:
LUX:ONEA'
s PB Ratio Range Over the Past 10 Years
Min: 1.18 Med: 3.16 Max: 16.19
Current: 2.51
During the past 13 years, Oneness Biotech Co's highest PB Ratio was 16.19. The lowest was 1.18. And the median was 3.16.
LUX:ONEA's PB Ratio is ranked better than 58.03% of 1227
companies
in the Biotechnology industry
Industry Median: 2.82
vs LUX:ONEA: 2.51
During the past 12 months, Oneness Biotech Co's average Book Value Per Share Growth Rate was -16.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -6.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Oneness Biotech Co was 52.20% per year. The lowest was -11.60% per year. And the median was 10.85% per year.
Back to Basics: PB Ratio
Oneness Biotech Co (LUX:ONEA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Oneness Biotech Co PB Ratio Related Terms
Oneness Biotech Co PB Ratio Historical Data
* Premium members only.
The historical data trend for Oneness Biotech Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Oneness Biotech Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oneness Biotech Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oneness Biotech Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Oneness Biotech Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Oneness Biotech Co (LUX:ONEA) has a PB Ratio of 6.86 as of Jul. 18, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oneness Biotech Co and its competitors. This is 117% above median its historical median of 3.16. Over the past decade, Oneness Biotech Co's PB Ratio has ranged from 1.18 to 16.19. According to the industry distribution chart, Oneness Biotech Co ranks #515 out of 1227 companies in the Biotechnology industry, placing it in the top 42%.
Is Oneness Biotech Co's PB Ratio too high?
Oneness Biotech Co's current PB Ratio of 6.86 is 117% above median its 10-year median of 3.16. Over the past 10 years, this metric has ranged from a low of 1.18 to a high of 16.19. The Biotechnology industry median PB Ratio is 2.82. Oneness Biotech Co's value of 6.86 is 143.3% above this industry median. Based on the distribution chart, Oneness Biotech Co ranks #515 out of 1227 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Oneness Biotech Co has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Oneness Biotech Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oneness Biotech Co ranks #515 out of 1227 companies for PB Ratio. This puts Oneness Biotech Co in the upper half of its industry. The industry median PB Ratio is 2.82. Oneness Biotech Co's value of 6.86 is 143.3% above this benchmark. Historically, Oneness Biotech Co's own PB Ratio has ranged from 1.18 to 16.19 over the past decade. While the company's 10-year median is 3.16 vs. the industry median of 2.82, Oneness Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oneness Biotech Co's current PB Ratio of 6.86 is 143.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Oneness Biotech Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oneness Biotech Co's current PB Ratio is 6.86, which is 117% above median its own 10-year median of 3.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oneness Biotech Co stock overvalued right now?
Oneness Biotech Co (LUX:ONEA) has a current PB Ratio of 6.86. The stock's GF Value™ is $35.65, compared to a current price of $23.60 — trading 33.8% below its estimated fair value. The current PB Ratio is 6.86, which is 117% above median its 10-year median of 3.16 and 143.3% above the Biotechnology industry median of 2.82. Oneness Biotech Co's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Oneness Biotech Co (LUX:ONEA), the current PB Ratio is 6.86 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oneness Biotech Co (LUX:ONEA) Overvalued in 2026?
Based on GuruFocus' analysis, Oneness Biotech Co stock appears to be undervalued.
The current stock price of $23.60 is trading 33.8% below its estimated GF Value™ of $35.65.
Key valuation signals for LUX:ONEA:
PB Ratio: 6.86 (117% above median its 10-year median of 3.16)
GF Value™: $35.65 vs. price of $23.60 (33.8% below fair value)
Industry Position: 143.3% above the Biotechnology median (#515 of 1227)
No single metric tells the full story. See the LUX:ONEA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oneness Biotech Co Ltd is engaged in the research and development of new drugs, the sale of pharmaceutical products and health products, and other related businesses. It focuses on developing drugs for the treatment of chronic skin and immune diseases. The Group's product portfolio comprises FESPIXON cream, for the treatment of diabetic foot ulcers, and Bonvadis, a wound care medical device. It also has various other product candidates in its development pipeline, such as FB825, FB704A, SNS812, SNS851, and others. The Group operates in the following reportable segments: New drug research and development, which derives maximum revenue, and the Agricultural products cultivation and organic food segment.
59GF Score
Get the complete analysis for LUX:ONEA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ONEA has been successfully added to your 
